Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash & Current Investments (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 3 years of Cash & Current Investments data on record, last reported at $195.0 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 39.06% year-over-year to $195.0 million; the TTM value through Dec 2025 reached $195.0 million, down 39.06%, while the annual FY2025 figure was $195.0 million, 39.06% down from the prior year.
  • Cash & Current Investments reached $195.0 million in Q4 2025 per INDV's latest filing, down from $445.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $510.0 million in Q2 2025 and bottomed at $195.0 million in Q4 2025.
  • Average Cash & Current Investments over 3 years is $375.5 million, with a median of $391.5 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: dropped 21.95% in 2024, then tumbled 39.06% in 2025.
  • A 3-year view of Cash & Current Investments shows it stood at $410.0 million in 2023, then decreased by 21.95% to $320.0 million in 2024, then crashed by 39.06% to $195.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $195.0 million in Q4 2025, $445.0 million in Q3 2025, and $510.0 million in Q2 2025.